Cyclin-Dependent Kinase (CDK) Inhibitors Therapeutics Pipeline Projects Vast Growth Ahead     |    CAD Software Market to Reach $11,097 Million by 2023     |    Friedreich’s Ataxia (FRDA) Therapeutics Pipeline to Receive Various Drug Designations from the USFDA and EMA in the Coming Years
P&S Market Research - A market research firm

Dry Eye Syndrome Therapeutics Pipeline Analysis 2017

P&S Market Research-Dry Eye Syndrome Therapeutics Pipeline Analysis report

Dry Eye Syndrome Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Published: June 2017
Report Code: LS11023
Available Format: pdf
Pages: 152

Disease Overview

Dry eye syndrome, also known as dry eye disease, keratitis sicca and keratoconjunctivitis sicca, is a form of ocular surface and tears disease that results in problems in vision, discomfort and tear film instability, causing potential damage to the ocular surface. It can also overlap with other causes of ocular surface disease such as meibomian gland dysfunction and ocular allergy. The ocular surface consists of seven components including the lacrimal and accessory lacrimal apparatus, the tear film, the nasolacrimal drainage system, the bulbar and tarsal conjunctiva, the eyelids, cranial nerve V and cranial nerve VII. Any abnormalities or deficiencies in one of these ocular surface components may worsen the condition of dry eye syndrome in a patient. Dry eye syndrome is categorized into two types which includes dry eye syndrome associated with sjögren syndrome and dry eye syndrome unassociated with sjögren syndrome. Dry eye syndrome can also be sub-divided into pure aqueous deficiency dry eye and evaporative dry eye.

Some of the symptoms associated with dry eye syndrome include hyperemia, ocular irritation, mucoid discharge, excessive tearing, blurred vision, photophobia, ocular dryness and grittiness. Dry eye syndrome can be treated by using lubricating supplements that includes artificial tear substitutes, gels, emulsions, ointments, topical anti-inflammatory agents such as topical cyclosporine, topical corticosteroids, topical or systemic tetracyclines, topical hyaluronic acid, autologous or umbilical cord serum, systemic immunosuppressants and topical or systemic omega-3 fatty acids.

Drug manufacturing companies are constantly in the quest to find better and new treatment strategies with potential targets such as glucocorticoid receptor and tumor necrosis factor-alpha (TNF-α) which can also prove to be effective in dry eye syndrome treatment. Various companies are developing drug candidates using different technologies for development of effective and better drugs, which is driving the growth of the pipeline.

Pipeline Analysis

As of June 2017, the dry eye syndrome pipeline comprises approximately 50 active drug candidates in different stages of development.

 

DRY EYE SYNDROME PIPELINE SPLIT, BY MOLECULE TYPE (2017)

DRY EYE SYNDROME PIPELINE ANALYSIS

Competitive Landscape

Some of the other key players developing drugs for the treatment of dry eye syndrome include Ocular Therapeutix, Inc., LTT Bio-Pharma, HanAll BioPharma Co., Ltd. and others.

Scope for Customization

P&S Market Research offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:

  • Market Forecast – Market analysis and forecast for the drug candidates in the latest stage of development
  • Company Profiles – Wider company coverage in terms of detailed analysis or additional company profiles

Place An Order

Single User License

Single User License authorizes access of the publication to single user, i.e. the buyer of the report.

2500
Group License

Group License authorizes access of the publication upto 5 users.

3250
Enterprise License

Enterprise License provides right to distribute copies of the publication across the organization and its subsidiaries.

7000
down-arrow

Pre-Purchase Enquiry

Contact Us

  • U.S. Center : 347 5th Ave. #1402- 210 New York City, NY 10016 United States
  • Asian Center : B-28, Sector 1, Noida, U.P. - 201301 India.

Secure Online Payments

  • Payment